Arcutis Biotherapeutics, Inc. (ARQT)

9.92 +0.44 (+4.64%) At close: 04:00PM EDT

Arcutis Biotherapeutics, Inc.

3027 Townsgate Road
Suite 300
Westlake Village, CA 91361
United States
805 418 5006
https://www.arcutis.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 296

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Todd Franklin Watanabe M.A.	President, CEO & Director	1.01M	N/A	1968
Dr. Bhaskar Chaudhuri Ph.D.	Co-Founder & Independent Director	60.83k	N/A	1955
Dr. Patrick E. Burnett M.D., Ph.D.	Senior VP & Chief Medical Officer	722.94k	N/A	1972
Mr. L. Todd Edwards	Senior VP & Chief Commercial Officer	755.64k	N/A	1964
Mr. David J. Topper	Senior VP & Chief Financial Officer	N/A	N/A	1958
Mr. Rajvir Madan	Chief Digital & Technology Officer	N/A	N/A	N/A
Ms. Latha Vairavan	Vice President of Finance & Investor Relations	N/A	N/A	N/A
Ms. Courtney Barton	VP and Chief Compliance Officer & Privacy Officer	N/A	N/A	1983
Mr. Masaru Matsuda Esq., J.D.	Senior VP, General Counsel & Corporate Secretary	626.22k	N/A	1971
Ms. Amanda Sheldon	Head of Corporate Communications	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Corporate governance

Arcutis Biotherapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 5. The pillar scores are Audit: 6; Board: 5; Shareholder rights: 3; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.